Do analysts rate KZIA or XTLB?

Novogen currently has a consensus price target of $26.33, suggesting a potential upside of 94.77%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Novogen is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, KZIA or XTLB?

XTL Biopharmaceuticals has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 532.11 -$13.41M N/A N/A XTL Biopharmaceuticals $450K 13.44 -$6.97M -$0.64 N/A

Is KZIA or XTLB more profitable?

Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A

Does the media refer more to KZIA or XTLB?

In the previous week, Novogen had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Novogen and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat Novogen's score of 0.72 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XTLB or ALLR?

Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 648.18%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XTLB or ALLR more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Allarity Therapeutics N/A -109.94% -47.27%

Does the media prefer XTLB or ALLR?

In the previous week, Allarity Therapeutics had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 5 mentions for Allarity Therapeutics and 2 mentions for XTL Biopharmaceuticals. Allarity Therapeutics' average media sentiment score of 0.97 beat XTL Biopharmaceuticals' score of 0.93 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend QNTM or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QNTM or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -674.48% -187.56% XTL Biopharmaceuticals N/A N/A N/A

Does the media favor QNTM or XTLB?

In the previous week, Quantum Biopharma had 5 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 7 mentions for Quantum Biopharma and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat Quantum Biopharma's score of -0.16 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MDXH or XTLB?

MDxHealth presently has a consensus target price of $2.83, indicating a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts clearly believe MDxHealth is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MDXH or XTLB more profitable?

XTL Biopharmaceuticals has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets MDxHealth -33.46% N/A -23.38% XTL Biopharmaceuticals N/A N/A N/A

Does the media favor MDXH or XTLB?

In the previous week, MDxHealth had 10 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 12 mentions for MDxHealth and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat MDxHealth's score of 0.57 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XTLB or LGVN?

Longeveron has a consensus price target of $8.00, suggesting a potential upside of 981.23%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer XTLB or LGVN?

In the previous week, Longeveron had 5 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 7 mentions for Longeveron and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat Longeveron's score of 0.00 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

XTL Biopharmaceuticals (XTLB) Competitors

$2.75 -0.05 (-1.79%)

Closing price 08/14/2026 02:58 PM Eastern

Extended Trading

$2.86 +0.11 (+3.96%)

As of 08/14/2026 04:54 PM Eastern

Compare

XTLB vs. KZIA, ALLR, QNTM, MDXH, and LGVN

Should you buy XTL Biopharmaceuticals stock or one of its competitors? XTL Biopharmaceuticals's main competitors and comparable companies include Novogen (KZIA), Allarity Therapeutics (ALLR), Quantum Biopharma (QNTM), MDxHealth (MDXH), and Longeveron (LGVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XTL Biopharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

Novogen currently has a consensus price target of $26.33, suggesting a potential upside of 94.77%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Novogen is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Novogen had 2 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Novogen and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat Novogen's score of 0.72 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	532.11	-$13.41M	N/A	N/A
XTL Biopharmaceuticals	$450K	13.44	-$6.97M	-$0.64	N/A

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
XTL Biopharmaceuticals	N/A	N/A	N/A

30.9% of Novogen shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Novogen beats XTL Biopharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Allarity Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

XTL Biopharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Allarity Therapeutics	N/A	-109.94%	-47.27%

In the previous week, Allarity Therapeutics had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 5 mentions for Allarity Therapeutics and 2 mentions for XTL Biopharmaceuticals. Allarity Therapeutics' average media sentiment score of 0.97 beat XTL Biopharmaceuticals' score of 0.93 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 648.18%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XTL Biopharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than Allarity Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.44	-$6.97M	-$0.64	N/A
Allarity Therapeutics	$320K	68.11	-$11.23M	-$0.72	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Allarity Therapeutics beats XTL Biopharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals' return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-674.48%	-187.56%
XTL Biopharmaceuticals	N/A	N/A	N/A

XTL Biopharmaceuticals has higher revenue and earnings than Quantum Biopharma. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
XTL Biopharmaceuticals	$450K	13.44	-$6.97M	-$0.64	N/A

In the previous week, Quantum Biopharma had 5 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 7 mentions for Quantum Biopharma and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat Quantum Biopharma's score of -0.16 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quantum Biopharma has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Summary

XTL Biopharmaceuticals beats Quantum Biopharma on 9 of the 11 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

XTL Biopharmaceuticals has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-23.38%
XTL Biopharmaceuticals	N/A	N/A	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MDxHealth has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

XTL Biopharmaceuticals has lower revenue, but higher earnings than MDxHealth. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.37	-$33.52M	-$0.65	N/A
XTL Biopharmaceuticals	$450K	13.44	-$6.97M	-$0.64	N/A

In the previous week, MDxHealth had 10 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 12 mentions for MDxHealth and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat MDxHealth's score of 0.57 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MDxHealth presently has a consensus target price of $2.83, indicating a potential upside of 250.66%. Given MDxHealth's stronger consensus rating and higher possible upside, research analysts clearly believe MDxHealth is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XTL Biopharmaceuticals beats MDxHealth on 9 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Longeveron?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Longeveron has a consensus price target of $8.00, suggesting a potential upside of 981.23%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Longeveron had 5 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 7 mentions for Longeveron and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.93 beat Longeveron's score of 0.00 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

XTL Biopharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. XTL Biopharmaceuticals' return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Longeveron	-1,977.59%	-223.19%	-150.20%

XTL Biopharmaceuticals has higher earnings, but lower revenue than Longeveron. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	13.44	-$6.97M	-$0.64	N/A
Longeveron	$1.19M	19.41	-$22.70M	-$0.99	N/A

XTL Biopharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market.

Summary

XTL Biopharmaceuticals and Longeveron tied by winning 8 of the 16 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.17M	$3.72B	$7.02B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-4.30	10.72	271.00	25.33
Price / Sales	13.44	1,241.21	583.09	76.83
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	-22.92	16.78	12.92	6.25
Net Income	-$6.97M	-$13.32M	$3.45B	$347.82M
7 Day Performance	-6.46%	1.75%	1.15%	1.08%
1 Month Performance	-6.14%	1.13%	1.37%	0.82%
1 Year Performance	N/A	54.35%	62.52%	20.99%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	0.6906 of 5 stars	$2.75 -1.8%	N/A	N/A	$6.17M	$450K	N/A	N/A	Gap Down
KZIA Novogen	3.3275 of 5 stars	$12.79 -7.9%	$25.80 +101.7%	+63.5%	$22.95M	$30K	N/A	12	News Coverage Analyst Forecast
ALLR Allarity Therapeutics	2.7057 of 5 stars	$1.40 -2.1%	$10.25 +632.1%	+39.8%	$22.75M	$320K	N/A	10	News Coverage Earnings Report Gap Up
QNTM Quantum Biopharma	0.4639 of 5 stars	$3.48 -2.0%	N/A	-83.0%	$22.72M	N/A	N/A	N/A	News Coverage Earnings Report Gap Up
MDXH MDxHealth	2.2472 of 5 stars	$0.47 +6.5%	$3.50 +645.3%	-71.5%	$21.83M	$107.88M	N/A	300	Trending News Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. KZIA, ALLR, QNTM, MDXH, and LGVN

How does XTL Biopharmaceuticals compare to Novogen?

Summary

How does XTL Biopharmaceuticals compare to Allarity Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Quantum Biopharma?

Summary

How does XTL Biopharmaceuticals compare to MDxHealth?

Summary

How does XTL Biopharmaceuticals compare to Longeveron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. KZIA, ALLR, QNTM, MDXH, and LGVN

How does XTL Biopharmaceuticals compare to Novogen?

Do analysts rate KZIA or XTLB?

Does the media refer more to KZIA or XTLB?

Which has more volatility and risk, KZIA or XTLB?

Which has stronger earnings and valuation, KZIA or XTLB?

Is KZIA or XTLB more profitable?

Do insiders & institutionals believe in KZIA or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Allarity Therapeutics?

Is XTLB or ALLR more profitable?

Does the media prefer XTLB or ALLR?

Do analysts prefer XTLB or ALLR?

Which has more volatility & risk, XTLB or ALLR?

Which has stronger valuation & earnings, XTLB or ALLR?

Do insiders & institutionals hold more shares of XTLB or ALLR?

Summary

How does XTL Biopharmaceuticals compare to Quantum Biopharma?

Do insiders & institutionals have more ownership in QNTM or XTLB?

Do analysts recommend QNTM or XTLB?

Is QNTM or XTLB more profitable?

Which has preferable valuation & earnings, QNTM or XTLB?

Does the media favor QNTM or XTLB?

Which has more risk and volatility, QNTM or XTLB?

Summary

How does XTL Biopharmaceuticals compare to MDxHealth?

Is MDXH or XTLB more profitable?

Do institutionals and insiders believe in MDXH or XTLB?

Which has more risk and volatility, MDXH or XTLB?

Which has better valuation and earnings, MDXH or XTLB?

Does the media favor MDXH or XTLB?

Do analysts recommend MDXH or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Longeveron?

Do analysts prefer XTLB or LGVN?

Do insiders and institutionals hold more shares of XTLB or LGVN?

Does the media prefer XTLB or LGVN?

Is XTLB or LGVN more profitable?

Which has preferable earnings and valuation, XTLB or LGVN?

Which has more volatility and risk, XTLB or LGVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools